EP Patent

EP3654969A1 — Methods of treatment for cystic fibrosis

Assigned to Vertex Pharmaceuticals Inc · Expires 2020-05-27 · 6y expired

What this patent protects

The invention relates to a compound I of formula (I) and / or a pharmaceutically acceptable salt (s) of compound I contained in a pharmaceutical composition and methods of using the composition for treating cystic fibrosis.

USPTO Abstract

The invention relates to a compound I of formula (I) and / or a pharmaceutically acceptable salt (s) of compound I contained in a pharmaceutical composition and methods of using the composition for treating cystic fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number: EP3654969A1
Jurisdiction: EP
Classification: —
Expires: 2020-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.